Table 1.

Demographics of patients, treatment received, and objective response

Patient IDAgeSexLine of treatment for metastatic diseaseAnti-EGFR therapyTumor response
Best responseDuration (wk)
159M4thPanitumumabPR31
262F3rdPanitumumabPR23
357M3rdPanitumumabSD15
478F4thPanitumumabPR24
563M3rdPanitumumabPR15
671M3rdPanitumumabSD32
760M4thPanitumumabSD24
858M4thPanitumumabPDNA
968M4thPanitumumabSD23
1056M2ndPanitumumabPDNA
1167F3rdPanitumumabPDNA
1254M3rdPanitumumabPDNA
1365F4thPanitumumabPDNA
1457M4thPanitumumabPDNA
1562F4thPanitumumabPDNA
1646F3rdPanitumumabPDNA
1753F4thPanitumumabPDNA
1867M3rdPanitumumabPDNA
1961M4thPanitumumabPDNA
2070F4thPanitumumabPDNA
2163F3rdPanitumumabSD15
2244M4thPanitumumabSD16
2347F3rdPanitumumabPDNA
2452F4thPanitumumabSD16
2553F4thPanitumumabSD31
2650F4thCetuximab + CTPR50
2758M4thCetuximab + CTPR45
2868M3rdCetuximab + CTPR47
2974M4thCetuximab + CTSD23
3073M4thCetuximab + CTPDNA
3139M4thCetuximab + CTPDNA
3254F5thCetuximab + CTPDNA
3378M1stCetuximabPR24
3484M1stCetuximabPR17
3575F1stCetuximabSD60
3674M1stCetuximabSD25
3757M1stCetuximabPDNA
3861M1stCetuximabPDNA
3971F1stCetuximabPDNA
4071M1stCetuximabPDNA
4176M1stCetuximabPDNA
4275F1stCetuximabPDNA
4376M1stCetuximabPDNA
4453M4thCetuximabPR50
4557M2ndCetuximab + CTSD33
4655M3rdCetuximab + CTSD25
4751M3rdCetuximab + CTPDNA
4859F3rdCetuximab + CTPR
  • Abbreviations: M, male; F, female; CT, computed tomography; SD, stable disease; PD, progressive disease; PR, partial response; NA, not applicable; —, data not available.